Get started
Author

Jairo Zuluaga

Microbiome as a prediction of immunotherapy response in lung cancer
2026 · Leonardo Rojas, Jairo Zuluaga, et al. · Frontiers in Immunology · 1
PDF
Lessons from PACIFIC-2 and the evolving landscape of unresectable stage III non-small cell lung cancer—when synergy blunts the benefit
2026 · Jairo Zuluaga, Juan Manuel Garzón-Dangond, et al. · AME Clinical Trials Review
Stage III Non-small Cell Lung Cancer Resectability in a Country With Limited Diagnostic and Therapeutic Resources: A Colombian Expert Consensus
2026 · Carlos A. Carvajal, Stella I. Martínez, et al. · Cancer Control
Automatic framework for PD-L1 expression evaluation in Latino patients with non-small cell lung cancer
2026 · Jorge Luis Rodríguez, Eduard Rodríguez, et al. · Journal of Pathology Informatics
Author response for "Stage III non-small cell lung cancer resectability in a country with limited diagnostic and therapeutic resources: A Colombian expert consensus"
2026 · Carlos A. Carvajal, Stella I. Martínez, et al. · Publons reviews and discussion
Overcoming immunotherapy resistance in non-small cell lung cancer: a narrative review of related factors.
2025 · Arrieta, Oscar, Zuluaga, Jairo, et al. · UNC Libraries
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
2024 · Jairo A. Zuluaga, Leonardo Rojas, et al. · AME Clinical Trials Review
Works count: 7
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type